Latest News and Press Releases

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

CERTARA APPOINTS DR. ADRIAN MCKEMEY AS PRESIDENT OF DRUG DEVELOPMENT SOLUTIONS

Dublin, Jan. 24, 2025 (GLOBE NEWSWIRE) -- The "Biosimulation Market Report 2025" has been added to ResearchAndMarkets.com's offering.The biosimulation market size is forecast to see rapid growth in...

Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Biosimulation Market (2024 Edition): Analysis By Type (Services, Software), By Application, By Deployment Model Outlook, By Region, By Country: Market...

Dublin, Dec. 12, 2024 (GLOBE NEWSWIRE) -- The "Biosimulation Market Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.The biosimulation market is projected to reach USD...

RADNOR, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today showcases its impact on research by celebrating more than 100...

Certara today announced the appointment of John Reynders, PhD to its Board of Directors, effective October 15, 2024.

Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.

Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001.